Background: Loss of CaMKII correlates with neuronal death following stroke and traumatic brain injury, yet whether this contributes to neurotoxicity is not known.
to excitotoxic glutamate signaling and inducing an excitotoxic insult itself.
INTRODUCTION:
Precisely-regulated calcium signaling is essential for normal neuronal growth and survival. While slight fluctuations in intracellular calcium concentration are tolerated by neurons, and necessary for a variety of physiological processes, dysregulation of intracellular calcium leads to neuronal death. Intracellular calcium overload can lead to mitochondrial depolarization and the overactivation of the downstream signaling pathways regulated by calcium. One important signaling pathway that is activated by calcium signaling is calcium/calmodulin (CaM)-dependent protein kinase II (CaMKII). Following activation with calcium-bound calmodulin, CaMKII targets to and phosphorylates a number of substrates in neurons, including voltage-and ligand-gated calcium channels, CREB, ERK, and voltagegated sodium channels (as previously reviewed (1-3)).
Fluctuations in CaMKII activity have been associated with neuronal disease states that exhibit excitotoxic calcium dysregulation, such as stroke, epilepsy, and traumatic brain injury (4) (5) (6) (7) (8) (9) (10) (11) . Immediately following the onset of excitotoxic stimulation, CaMKII is activated (5, 9) and inhibition of CaMKII prior to excitotoxic insult prevents neuronal damage both in vitro and in vivo (12) (13) (14) (15) (16) (17) . However, αCaMKII knock-out animals paradoxically exhibit a significant increase in neuronal damage following stroke compared to wild-type littermates (18) . Moreover, we recently showed that prolonged pharmacological inhibition of CaMKII actually exacerbated excitotoxicity following a submaximal glutamate challenge (12) . Thus, while an acute loss of CaMKII may protect neurons from excitotoxic insult, a prolonged loss of CaMKII activity sensitizes neurons to glutamate toxicity; an observation we hypothesize contributes to programmed cell death in the penumbral region associated with ischemia and brain trauma. In support of this hypothesis, a loss of CaMKII activity has been shown to be spatially correlated with the extent of neuronal damage following focal ischemia (8) . The region immediately surrounding the infarct not only displays the greatest damage but also the greatest loss in CaMKII activity (8) . However, the ischemic environment is associated with complex biochemical changes that are associated with aberrant glutamate signaling, including enhanced ROS activity, acidosis, and a decrease in energy availability. Thus, we choose to investigate neuronal survival, calcium signaling, and excitability following a loss of CaMKII activity induced by a broad spectrum of CaMKII inhibitors in the absence of an exogenous glutamate challenge. Our data supports a model whereby prolonged inhibition of CaMKII produces apoptosis in cortical neurons by a feed-forward process associated with neuronal hyperexcitabilty and dysregulated calcium and glutamate signaling.
EXPERIMENTAL PROCEDURES:
Materials. Unconjugated tat (YGRKKRRQRR), CN21
(KRPPKLGQIGRSKRVVIEDDR), CN21Ala (KAPAKAAWAAASKRVVIEDDR), CN21C (GQIGRSKRVVIEDDRIDDVLK), tat-AIP (YGRKKRRQRR-RKKLRRQEAFDAL), tat-CN21, tat-CN21Ala, as well as Fam-labeled versions of these peptides were synthesized and HPLC purified by Biopeptide Co, Inc. San Diego, CA, USA. Myristolated AIP (myr-AIP; 64929) was purchased from Anaspec, Fremont, CA. KN-93 (422708) and KN-92 (422709) were purchased from Calbiochem, EMD Biosciences, La Jolla, CA. STO-609 (1551) was purchased from Tocris Bioscience, Ellisville, MO. MK-801 (M107), Nifedipine (N7634), Nimodipine (N149), Tetrodotoxin (T8024), OmegaConotoxin (C9915), Ifenprodil (I2892), and Memantine (M9292) were purchased from Sigma Aldrich, St. Louis, MO. Neuronal cultures. Cortical neurons were harvested from E18-E19 Sprague-Dawley rat pups according to approved IACUC guidelines as previously described (12) . Primary hippocampal neurons were prepared from postnatal day 1 Sprague-Dawley rat pups as previously described (19, 20) . For most experiments, cortical neurons were seeded at a density of 2.5 million cells/mL and seeded on poly-D-lysine (50 µg/mL) coated 15 mm coverslips (German glass Number 0) or 60 mm dishes. For experiments looking at neuronal viability at different stages of culture development, neurons were seeded at 1.25 million cells/mL. Cultures were treated with 5-fluor-2'-deoxyuridine (15 mg/mL) (Sigma, F0503) and Uridine (35 mg/mL) (Sigma, U3750) to kill mitotically active cells on day 2-4. Co-cultures of neurons and astrocytes were not treated with these mitotic inhibitors. Cell Death Assay. Following treatment, the coverslips were washed in PBS and stained using Live/Dead Cytotoxicity/Viability kit (Molecular Probes, Eugene, OR) as previously described (12) . Each coverslip is imaged in three different fields using a Texas Red filter to detect cytotoxic cells and a FITC filter to detect viable cells on a Nikon Ti-E inverted microscope (100x magnification). Cells were quantified using the automated counting software Nikon Elements 3.0 as previously described (12) . Total cell number was determined by addition of cytotoxic and viable cells. Complete media exchanges and washing conditions routinely induced cytotoxicity in about 5-10% of cultured neurons.
Immunocytochemistry of neuronal cultures.
Neurons (8-9 DIV) treated with CaMKII inhibitors were fixed in 4% paraformaldehyde (0.1 M phosphate buffer, pH 7.4) for 10 min and washed in phosphate buffered saline (PBS) three times. For labeling, cells were permeabilized in 0.5% Triton X-100 in PBS for 10 minutes at room temperature, washed in PBS three times, blocked for 1 hour in 2% BSA Fraction V, 20% normal goat serum, 0.1% Triton X-100 in PBS at room temperature, washed an additional three times in PBS. Cells were then incubated in primary polyclonal cleaved caspase 3 antibody (1:500, Cell Signaling (#9661), Beverly, MA) for 2 hours at room temperature. After three washes, secondary antibodies (anti-rabbit Alexa 594 , 1:5000 (Molecular Probes, Eugene, OR)) were applied for one hour at room temperature. Coverslips were washed in PBS three times and were subsequently mounted in Prolong Gold Antifade with DAPI mounting media (Molecular Probes) and cells were imaged using a Zeiss Axio ObserverZ1 and processed with Axiovision 4. CaMKII Activity Assay. Neuronal cultures were lysed in lysis buffer containing (50 mM HEPES pH 7.4, 4 mM EGTA, 10 mM EDTA, 15 mM Na 4 P 2 O 7 -10H 2 0, 100 mM β-glycerophosphate, 25 mM NaF, 1% Triton-X 100, and protease inhibitor cocktail (Calbiochem, 539137) as described previously (21) , sonicated, and incubated with 50 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl 2 , 100 µM ATP, 2 mM CaCl 2 , 5 µM CaM, 50 µM AC2 (KKALRRQETVDAL), and [γP 32 ]-ATP (3µCi per reaction) for 3 minutes at 30 o C. The linear range of the reaction extended from 30 seconds to 4 minutes. Protein levels were assessed and activity was normalized to total protein using DC protein assay kit (Biorad, Hercules, CA). Calcium Imaging. Hippocampal neurons 10-12 DIV were loaded with 2.6 M Fura-2FF-AM (Molecular Probes, Invitrogen) and 1.7 M Rhodamine 123 and subsequently imaged as previously described (20, 22) . During imaging, the neurons were maintained in a bath solution containing 10 mM HEPES, pH 7.4, 139 mM NaCl, 3 mM KCl, 0.8 mM MgCl 2 , 1.8 mM CaCl 2 , 5 mM glucose and 65 mM sucrose. For Fluo-4 experiments, cortical neurons were incubated with 5 µM Fluo-4-AM (Molecular Probes, Invitrogen) diluted in rat physiological saline (138 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl 2 , 1.06 mM MgCl 2 , 12.4 mM HEPES pH 7.4, 5.6 mM glucose; final pH adjusted to 7.3) for 30 minutes at 37°C. Following incubation cells were washed with rat physiological saline 3 times for 5 minutes each. A Nikon Ti-E inverted microscope with a FITC filter was employed to monitor Fluo-4 levels once every thirty seconds. Baseline was monitored for 5 minutes. In all experiments with CaMKII inhibitor application, the inhibitor was added 10 minutes after start of imaging, some experiments called for the addition of other inhibitors as indicated. For these, the drugs were applied at the 5 minute mark in order to identify whether the drug itself had an impact on calcium levels prior to CaMKII inhibitor application at minute 10. Analysis was performed using Nikon Elements v3.0 in which Fluo-4 levels were measured in ~20 cells per field and 3 fields per coverslip. Neurons were identified at the start of the experiment with a 20mM KCl depolarization with a subsequent wash. The fluorescent intensity of each cell was normalized to time 0, as the drug was applied. Electrophysiology. Action potential studies were carried out using the whole cell patch-clamp technique under the current clamp mode. Whole cell voltages were recorded with HEKA software (HEKA electronic). The neuronal growth media on the cortical neurons (8-10 DIV) was gradually replaced by the extracellular recording solution before the patch clamp recording. The extracellular solution consisted of rat physiological saline (as described above). The intracellular solution contains 140 mM potassium gluconate, 2 mM KCl, 3 mM MgCl 2 , 10 mM HEPES, 5 mM phosphocreatine, 2 mM K-ATP, 0.2 mM Na-GTP; final pH adjusted to 7.4. Pipette resistance was 2-4 MΩ when filled with the internal solution. Data were acquired and analyzed using the Pulsefit software following previously established protocols (23, 24) . Cortical neurons were held at their resting potentials by injection of steady current throughout the experiment. To determine the current threshold for action potential initiation, neurons were injected with a series of depolarizing currents with variable amplitudes for 200 ms. The sampling frequency was 10 kHz. Following identification of the current threshold for action potential generation, the neurons were injected with a 1 second depolarizing ramp current that subsequently elicited one to two action potentials. Neurons that maintain initial resting membrane potentials more negative than -50 mV after whole cell configuration and had less than 3 action potentials at the starting point were included in this study. We compared the change in the number of APs obtained 10 minutes after establishing the whole cell configuration to the number obtained at the initial starting time point when the peptide had not diffused into the intracellular environment. The current clamp studies were performed at room temperature (~ 21°C). 
RESULTS:

Neurotoxicity with CaMKII Inhibition
To test the hypothesis that CaMKII inhibition induces neuronal death, we subjected cortical neurons (8 DIV) to acute (1 hour) and prolonged (24 hours) pharmacological inhibition of CaMKII using multiple inhibitors. Peptides derived from the endogenous inhibitor of CaMKII, termed CN21, and the autoinhibitory domain of CaMKII itself (AIP) were used because of their high specificity to inhibit CaMKII (26-28). As previously described (12, 13, 27) , conjugation of peptide inhibitors to the cell-penetrant motif, tat, affords the ability to examine the effects of CaMKII inhibition with cell penetrating peptides in both cultures and in vivo. In addition to the peptide inhibitors, we also utilized the allosteric CaMKII inhibitor KN-93 (12, (27) (28) (29) . We applied 10 µM tat-CN21, tat-AIP, and 1 µM KN-93 to cortical neuronal cultures for 1 or 24 hours and subsequently examined viability/cytotoxicity levels 24 hours following the start of treatment (12) . To compensate for the decreased bioavailability associated with tat-based peptides accumulating in non-cytoplasmic compartments (30) , the concentrations of the peptide inhibitors used in this study are roughly 100 fold above the in vitro IC 50 for CN21 (77-100 nM) (12, 27) . To control for potential off target effects, we applied KN-92, the inactive control for KN-93, or a peptide control, tat-CN21-Ala (12) . For each neuronal death experiment, data was normalized by subtracting average neuronal death observed in control cultures. The control cultures in each experimental group consistently exhibited 5-10% toxicity. Cortical neuron viability was no different than control cultures (DMSO treated) when CaMKII inhibitors were applied for one hour (Fig. 1A, gray bars) . In contrast, all three CaMKII inhibitors (KN93, tat-CN21, tat-AIP) significantly increased neuronal death 12-18% when applied for 24 hours (Fig. 1A, black bars) . Compared to control cultures, lower concentrations of tat-CN21 also induced neurotoxicity when applied overnight (1 µM tat-CN21 5.3% ± 2.4%; p<0.05). Importantly, cultures treated with the inactive controls, tatCN21Ala and KN-92, for 24 hours did not exhibit significant changes in neuronal viability (Fig. 1A) , suggesting that the neurotoxic effects are specific to the application of active small molecule and peptide CaMKII inhibitors. Furthermore, the tat motif, itself, was not toxic when applied for 24 hours (0.533 ± 1.6%; p>0.5). Utilization of a myristolated-AIP peptide inhibitor of CaMKII also induced neurotoxicity (29.6 ± 4.2%; p<0.05). Thus, CaMKII inhibition using both small molecule and peptide inhibitors conjugated to tat and myristolated cellpenetrating motifs induce neuronal death when applied for 24 hours.
While a significant increase in neurotoxicity was observed within our neuronal cultures when CaMKII was inhibited at 8 DIV, we tested whether the age of the culture affected this neuronal death. While no differences were observed in neuronal viability between control groups at 8 DIV, 14 DIV and 21 DIV, 24 hour inhibition of CaMKII with tat-CN21 significantly enhanced neurotoxicity with respect to time in culture (Fig. 1B) . Compared to cultures 8 DIV, 14 DIV cultures exhibited nearly 25% toxicity while nearly 75% of cells were compromised when CaMKII was inhibited at 21 DIV. The cell death observed with CaMKII inhibition is not limited to highly enriched cortical cultures (>95% MAP-2 immunopositive (12)), as a similar level of toxicity was observed in neurons cultured with glia ( Fig. 1C ). In these co-cultures, a monolayer of GFAP positive astrocytes underlying MAP2 positive cortical neurons represent an astrocytes to neurons ratio of 3:2 (Supplemental Fig. 1 ). Thus, the toxicity produced by CaMKII inhibition is enhanced by culture age and observed in both highly pure cultures of cortical neurons as well as cortical neurons cultured with astrocytes.
In Fig. 1A we report that CaMKII inhibition for acute (1 hour) versus prolonged (24 hours) differentially affects neuronal death. To determine the minimal time where CaMKII inhibition-induced cell death, we applied tat-CN21 for various times between 1 and 24 hours. In addition, we explored exposure times longer than 24 hours to determine if neurotoxicity was saturated. Once again, a 1 hour exposure of neurons to tat-CN21 failed to produce cell death ( Fig. 2A) . CaMKII inhibition for 4 hours or less was also not toxic to neurons ( Fig. 2A) . Progressively increasing neuronal death as a function of CaMKII inhibition time was observed up to 12 hours. However, longer incubation times (24 or 48 hrs) did not produce additional neurotoxicity ( Fig. 2A) , suggesting that events occurring within the first 12 hours largely determine the neuronal death associated with CaMKII inhibition.
The extent of CaMKII inactivation produced by focal ischemia in vivo was previously shown to correlate with the extent of neuronal damage (8) . Because we observed a time-dependence in the neurotoxicity produced by CaMKII inhibition, we determined if neuronal death in cortical cultures is correlated with functional changes in CaMKII. We observed a timedependent loss in the activatable pool of CaMKII that correlated with exposure time of the CaMKII inhibitor. Application of tat-CN21 for ≥4 hours resulted in a significant decrease in activatable CaMKII compared to vehicle-treated control neurons (Fig. 2B) . A maximal 50% loss of activity occurred when tat-CN21 was applied for 24 hours. Importantly, neurons treated with inactive tat-CN21Ala for 24 hours did not exhibit a decrease in activatable CaMKII (Fig.  2B) .
We previously showed that neuronal uptake of fluorescent carboxyfluorescein (Fam) labeled tat-CN21 and control tat-CN21Ala (Fam conjugated to the C-terminus) were similar in our cortical cultures (12) . Using these Famlabeled peptides, we measured peptide uptake and neuronal death in order to identify whether fluorescently labeled neurons are preferentially dying in our assay. Using fluorescent microscopy, we observed that ~25% of cells display substantial tat-CN21-Fam or tatCN21Ala-Fam uptake (Supplemental Fig. 2 ). However, a large proportion of cells exhibit low, but still above background levels of fluorescent peptide, suggesting that CaMKII activity may be reduced in more than the 25% of cells. It is noteworthy that peptide uptake (~25%) correlates with neuronal death (~25%). The disconnect between maximal cell death (~25%) and the 50% decrease in CaMKII activity could be explained by the observation that not all cells exhibit the same levels of peptide uptake, suggesting that low levels of CaMKII inhibition may not reach a threshold that is required for neurotoxicity. While the mechanism behind the differential peptide uptake and loss of CaMKII activity is not known, there is a clear correlation with cytotoxicity and CaMKII inhibitor uptake as nearly 80% of cytotoxic cells exhibit tat-CN21-Fam co-localization (Supplemental Fig.  2 ).
CaMKII Inhibition Induces Apoptosis
The time-dependence of CaMKII inhibition (>4 hours) leading to toxicity is consistent with apoptosis. To test if neurons were undergoing apoptosis in response to prolonged CaMKII inhibition, cultures were co-treated with tat-CN21 and the protein translation inhibitor cycloheximide. Co-application of 0.5 mg/mL cycloheximide blocked tat-CN21-induced neurotoxicity (Fig. 3A) . Similarly, co-treatment of tat-AIP and cycloheximide abolished the tat-AIP-induced toxicity (Supplemental Fig. 3 ). In further support of apoptosis, there was a significant increase in TUNEL staining of cultures treated with tat-CN21 for 24 hours compared to control and cultures co-treated with 0.5 mg/mL cycloheximide (Fig. 3B) . To confirm that the apoptosis occurred within cells that took up the CaMKII inhibitors, we next examined levels of activated caspase-3, a neuronal marker for apoptosis. Overnight application of tat-CN21-Fam was used in order to identify neuron uptake of the CaMKII inhibitor. Activated caspase-3 labeling was limited to cells that contained tat-CN21-Fam (Fig. 3C) . Not all neurons that were tat-CN21-Fam positive displayed caspase-3 activation. However, nearly all of the neurons that contained tat-CN21-Fam had pyknotic and fragmented nuclei, indicating that the neurons were compromised (Fig. 3C) . Thus, while some necrotic cell death may not be ruled out, CaMKII inhibition does lead to apoptosis.
Calcium
Dysregulation with CaMKII Inhibition
One prominent mechanism underlying neurodegeneration is dysregulated calcium signaling (as reviewed by (31)). Cultured hippocampal neurons (DIV 14) were loaded with Fura-2FF-AM and intracellular calcium levels were measured using ratiometric fluorescent imaging. While tat-CN21Ala or tat did not alter intracellular calcium levels, tat-CN21 led to a gradual rise in intracellular calcium ( Fig. 4B-D) , suggesting that CaMKII inhibition leads to a slow, tonic increase in intracellular calcium. This calcium dysregulation is also observed in cortical neurons loaded with Fluo-4AM. Using this high affinity calcium indictor, we observed significantly elevated intracellular calcium levels occurring within 10 minutes exposure to tat-CN21 application (Fig.  4E-F) . Again, no changes in intracellular calcium were observed with tatCN21-Ala (Fig.  4E ). Similar to tat-CN21, 10 µM tat-AIP (data not shown) and 10 µM myristolated-AIP (Fig.  4F ) induced a significant increase in intracellular calcium concentration. In contrast, inhibition of the CaMKK pathway (CaMKI and CaMKIV (32, 33) ), using STO-609, does not induce calcium dysregulation (Fig. 4F) . Thus, acute CaMKII inhibition leads a slow increase in intracellular calcium levels.
Low extracellular calcium largely prevented the tat-CN21-induced calcium influx (Fig. 4F) , indicating that calcium influx is likely derived from extracellular sources. L-type voltage-gated calcium channels do not appear to contribute to this process because pretreatment with 10 µM nimodipine had no effect on tat-CN21 induced calcium dysregulation (Fig. 4F) . However, synaptic transmission may contribute to the increase in intracellular calcium, as 1 µM N-type calcium channel blocker omega-conotoxin abolished calcium dysregulation prior to tat-CN21 treatment. Because N-type calcium channels play a prominent role in synaptic activity, we tested if neuronal activity was essential for this process by inhibiting AMPA receptors. Indeed, inhibition of AMPA receptors, using 10 µM CNQX, blocked calcium dysregulation following CaMKII inhibition. In further support for neuronal activity being essential for the tonic increase in intracelluar calcium observed with CaMKII inhibition, inhibition of voltage-gated sodium channels using TTX (1 M) prior to tat-CN21 treatment completely abolished the calcium influx (Fig.  4F) . These data are consistent with neuronal activity being essential for the calcium influx associated with inhibition of CaMKII.
Enhanced Neuronal Excitability with CaMKII Inhibition
To address the potential for CaMKII inhibition to alter neuronal excitability, we employed whole cell current-clamp to measure action potential firing in response to a depolarizing voltage ramp. In these experiments we used lower peptide concentration (1 M) because the patch pipette provides direct access to the cytosol. We used inhibitory peptides without the cell-penetrating tat motif to affect only the cell from which we were recording. Each cell served as its own control by determining the number of action potentials generated immediately after establishing whole-cell configuration versus 10 minutes later when the peptide inhibitors have had the opportunity to diffuse from the pipette to inhibit CaMKII. Cortical neurons exposed to 1 µM CN21 for 10 minutes exhibited a three-fold increase in the number of action potentials compared to neurons treated with 1 µM inactive peptide CN21Ala (Fig. 5A-B) . CN21C, another previously established control for CN21 (12, 13) , did not result in a significant increase in action potential number compared to baseline. Overall, these data support the hypothesis that CaMKII inhibition enhances neuronal excitability.
CaMKII Inhibition Predisposes Neurons to Excitotoxic Insults
Our observed increase in neuronal excitability with a loss of CaMKII activity supports previous reports indicating that genetic αCaMKII knockout animals are predisposed to epilepsy (34) . We hypothesize that this increased excitability not only underlies the observed neurotoxicity, but also mechanistically underlies the decreased ability of the neurons to handle excitatory insults. As mentioned, αCaMKII knock-out animals also exhibit greater neuronal damage following middle cerebral artery occlusion than their wild-type littermates (18) . Similarly, overnight inhibition of CaMKII with tat-CN21 exacerbated cortical cell death following application of exogenous glutamate in an in vitro model of excitotoxicity (12) . To further explore the role of CaMKII inhibition in sensitizing neurons to excitotoxic-related insults, we sought to identify whether prolonged CaMKII inhibition predisposed neurons specifically to NMDA-R activation and/or sensitized neurons to the deleterious effect of reactive oxygen species. Thus, 10 µM tat-CN21 was applied to cortical neurons for 24 hours. Following overnight inhibition of CaMKII, the neurons were subjected to submaximal levels of 100 µM NMDA/10 µM glycine or H 2 O 2 for 5 minutes, washed, and 24 hours later cell viability assessed. Compared to cultures that were treated with NMDA for 5 minutes alone, cultures subjected to CaMKII inhibition prior to NMDA-R stimulation exhibited significantly increased neuronal death (15% vs 45%) (Fig. 6) . Similarly, neurons treated with tat-CN21 also exhibited significantly higher levels of toxicity when treated with H 2 O 2 , compared to H 2 O 2 alone (Fig. 6) . Neuronal sensitivity to Microcystin-LR, a cell-permeable protein phosphatase 1 and 2A inhibitor, was also assessed as CaMKII activity has been shown to be necessary for microcystin-induced apoptosis (35) . Interestingly, prolonged CaMKII inhibition was not synergistic nor additive with microcystin toxicity (Fig. 6) , suggesting that CaMKII inhibition via tat-CN21 blocks neurotoxicity produced by microcystin treatment and that the neuronal death induced by CaMKII inhibition is not obstructed by protein phosphatase inhibitors. Together these data suggest that a prolonged loss of CaMKII sensitizes neurons to ROS and NMDA-R mediated excitotoxicity. Thus, CaMKII inhibition appears toxic to neurons both directly via inducing calcium dysregulation and hyperexcitabilty and indirectly through predisposing neurons to glutamate excitotoxicity.
Glutamate Dysregulation with CaMKII Inhibition
Because a loss of CaMKII predisposes neurons to glutamate excitotoxicity, we questioned whether CaMKII inhibition itself affected glutamate levels within our cultures. To address this question, cultures were treated with tat-CN21 for varying lengths of time and glutamate concentration in the media was assessed using a glutamate oxidase assay. There was a significant increase in glutamate concentration in the media as early as 20 minutes following tat-CN21 application (Fig. 7A) . Twenty-four hours following tat-CN21 application the concentration of glutamate in the bath solution was 4-5 µM while tat-CN21Ala failed to raise glutamate levels compared to control without treatment (0.5-1 M). Similarly, HPLC analysis of glutamate concentration in the media also indicated that 24 hour application of tat-CN21 resulted in more than a two-fold elevation in glutamate concentration compared to inactive tat-CN21Ala (Supplemental Fig. 4) .
To determine whether this slight elevation in glutamate is important for calcium dysregulation and cell death, we sought to attenuate the glutamate rise enzymatically to dissociate CaMKII inhibition with the increased extracellular glutamate. Glutamate pyruvate transaminase (GPT), in the presence of pyruvate, catalyzes the conversion of glutamate to -ketoglutarate and alanine (35) . Thus, we added 0.25 mg/mL GPT and 2 mM pyruvate in combination with the CaMKII inhibitory peptide tat-CN21 to the cortical neurons and measured extracellular glutamate levels using the oxidase assay. Twenty-four hour application of tat-CN21 resulted in a significant increase in glutamate in the media of the cultured cortical neurons (Fig.  8A) . Co-application of GPT and pyruvate with tat-CN21 brought glutamate levels back to control. When pyruvate was omitted from the treatment, a significant increase in glutamate concentration was seen with tat-CN21 (Fig. 8A) . Furthermore, when GPT was boiled prior to application, GPT and pyruvate failed to bring tat-CN21-induced glutamate release back to control levels (Fig. 8A) .
Having successfully buffered the prolonged rise in extracellular glutamate when CaMKII was inhibited, we measured acute changes in intracellular calcium concentrations with Fluo-4AM when GPT and pyruvate was present. As before, 10 µM tat-CN21 induced significant dysregulation of intracellular calcium concentrations within minutes of application (Fig. 8B) . Interestingly, application of GPT and pyruvate prevented tat-CN21-induced calcium influx (Fig. 8B) . Co-application of tat-CN21 with pyruvate alone did not alter calcium influx with CaMKII inhibition (0.85 ± .24, normalized to tat-CN21).
Neuronal viability following CaMKII inhibition was also assessed with extracellular glutamate buffering. Consistent with the glutamate experiments, the tat-CN21-induced neurotoxicity was abolished by co-treatment with GPT and pyruvate (Fig. 8C ). Cultures treated with GPT/tat-CN21 exhibited a statistical increase in neuronal death, similar to cultures treated with tat-CN21 alone (Fig. 8C ). Significant neurotoxicity was also observed when cultures were treated with pyruvate and tat-CN21 (19.077 ±1.876%). Once more, both omission of pyruvate and boiling of GPT prior to application resulted in a failure in preventing tat-CN21-induced neurotoxicity (Fig. 8C) . Together, these data indicate that enzymatically degrading the glutamate released after CaMKII inhibition prevents calcium dysregulation and neuronal death.
We next examined if calcium entering through glutamate receptors, specifically the NMDA receptors contributes to the observed calcium influx. Application of 20 µM MK-801 reduced tat-CN21-induced calcium influx by ~80% (Fig.  9A) . As mentioned earlier, the calcium influx induced by CaMKII inhibition was also blocked by pharmacological antagonism of synaptic activity (via blockade of VGSCs, AMPA-Rs, and VGCCs). To determine the contribution of synaptic NMDA receptors in this calcium dysregulation, cortical neurons were treated with bicuculline to induce synaptic activity by inhibiting GABAergic signaling as described previously (36, 37) . Rapid increases in cytoplasmic calcium were observed with bicuculline treatment. MK-801 was added immediately following exposure to bicuculline to block the open NMDA-Rs (38) (Supplemental Fig. 5 ). The CaMKII inhibitor, tat-CN21, was then applied and subsequent changes in intracellular calcium concentration were monitored. Interestingly, this blockade of synaptic NMDA-Rs significantly blunted tat-CN21-induced calcium influx (Fig. 9A) . However, this treatment did not maintain levels of intracellular calcium to those observed in control, indicating that while much of the calcium influx observed with CaMKII inhibition was via the synaptic NMDA receptors, calcium entering through extrasynaptic NMDA-Rs may also contribute to this process.
Because antagonism of the NMDA receptor successfully blunted the acute increase in calcium influx, we hypothesized that MK-801 would also reduce the neurotoxicity induced by CaMKII inhibition. Compared to cultures treated with tat-CN21 alone, neurotoxicity was reduced nearly 80% when tat-CN21 was co-applied with 20 µM MK-801 (Fig. 9B) . We next attempted to block extrasynaptic NMDA-Rs to determine the influence of extrasynaptic versus synaptic NMDA-Rs to the neurotoxicity induced by CaMKII inhibition. Low levels of ifenprodil and memantine have been shown to be preferential antagonists to the NR2B-containing extrasynaptic NMDA-Rs (39, 40) . There was still a significant increase in the observed neurotoxicity when tat-CN21 was co-applied with 10 µM ifenprodil or 1 µM memantine, with neither drug affecting viability alone (Fig. 9B) . However, ifenprodil does reduce the levels of toxicity below that observed with tat-CN21 alone (Fig. 9B) , suggesting that extrasynaptic NMDA-Rs may play a partial role in the toxicity associated with the loss of CaMKII signaling. Increasing the dose of memantine to 10µM, a level that inhibits not only extrasynaptic NMDA-Rs but also partially inhibits synaptic NMDA-Rs, does significantly reduce neuronal death (13.6 ± 4.6%). When cultures were treated with low levels of TTX (200 nM) to block action potential-induced synaptic activity, tat-CN21-induced toxicity was brought back to baseline (Fig. 9B) . Thus, while extrasynaptic NMDA-Rs cannot be ruled out, it is quite convincing that synaptic activity is necessary for both the calcium dysregulation and neurotoxicity associated with a loss of CaMKII signaling (39, 40) . In total, these data suggest that CaMKII inhibition induces a slow-tonic excitotoxic event via calcium dysregulation, enhanced neuronal excitability, and augmented extracellular glutamate levels.
Finally, to determine if the accumulation of glutamate in the bath solution was solely responsible for this neurotoxicity, cortical neurons were treated for 24 hours with 10 µM tat-CN21. Then, the conditioned media was removed from these cultures and directly applied to naïve cortical neurons. Neurons treated with the conditioned media did not display a significant difference in viability compared to non-treated control cultures (Fig. 10) . We also did not observe significant neuronal death when 4 µM glutamate was applied to our cortical cultures for 24 hours (6.9 ± 3.1% vs control 5.8 ± 2.2%), suggesting that this glutamate concentration in the media is not sufficient to induce neuronal death in the absence of CaMKII inhibition.
Thus, while the increased extracellular glutamate resulting from CaMKII inhibition is necessary for the observed neurotoxicity (Figs 8 and 9) , it is not sufficient to produce the toxicity itself. Together, these data indicate that the combination of elevated glutamate with the loss of CaMKII activity induces toxicity. Thus, the mechanism underlying the neurotoxicity with CaMKII inhibition is the decreased ability of neurons to tolerate glutamate stimulation, including the stimulation resulting from the low levels of glutamate associated with the neuronal hyperactivity directly resulting from CaMKII inhibition.
DISCUSSION
Prolonged CaMKII inhibition using both small molecule (KN-93) and peptide (tat-AIP, myr-AIP, and tat-CN21) inhibitors is toxic to cultured neurons in the presence and absence of astrocytes. Although an acute one hour exposure is not toxic, all of these inhibitors produced neuronal death after 24 hours. We elected to use pharmacological approaches over genetic knockdown of CaMKII in order to better mimic the time-course of CaMKII inactivation associated with ischemic brain trauma and other diseases associated with aberrant neuronal activity. Pharmacological inhibitors afford the opportunity to determine acute changes in neuronal activity and calcium homeostasis with CaMKII inhibition. Plus, the CaMKII inhibitors used are not thought to display any isoform specificity, avoiding potential complications associated with isoform compensation associated with genetic knockdown. Multiple pharmacological inhibitors (small molecule and peptide) employing different methodologies for cell uptake (cell permeable small molecule versus tat and myristolated peptide import strategies) were used to limit the possibility of off-target effects confounding our conclusions.
The concentration of tat-CN21 (10 M) used throughout this study is similar previous studies using this CaMKII inhibitor to explore neurite extension (27) and neuroprotection to a glutamate-insult (12, 13) . Although these values are ~100 fold over the IC 50 for CN21 in vitro (12, 27) , cell uptake and bioavailability can be limiting for intracellular peptide inhibitors (30) , making the peptide concentrations used in this and other studies reasonable pharmacological concentrations. Finally, previously established inactive controls for KN-93 (KN-92) (27) and tat-CN21 (tat-CN21Ala) (12) did not induce neuronal death at the concentration of the active inhibitors that clearly produced toxicity, suggesting that the neuronal toxicity observed is due to CaMKII inactivation.
Prolonged CaMKII inhibition is consistent with features of both necrotic and apoptotic cell death. Apoptotic cell death is supported by the following observations: 1) application of the inhibitors required an incubation period of >8 hours to induce toxicity, 2) inhibitor application led to an increase in TUNEL staining, 3) colocalization between neurons that take up fluorescent tat-CN21 and cleaved caspase-3 was observed, and 4) cell death was prevented by the protein translation inhibitor, cycloheximide. The pro-apoptotic Bcl-2-associated death promoter (BAD) protein is inactivated by CaMKII phosphorylation. Thus, it is possible that the prolonged inhibition of CaMKII activity dysinhibits the BAD cascade, leading to apoptosis (41) . A population of neurons containing the CaMKII inhibitor did not exhibit caspase-3 staining, yet these neurons consistently exhibited morphological changes in the nucleus (condensation and fragmentation). It is unclear whether these neurons represent a continuum between necrosis and apoptosis, or whether this could be specifically related to apoptosis with secondary necrosis (42) .
CaMKII inhibition results in a slow sustained increase in intracellular calcium levels that is accompanied by elevated glutamate and enhanced neuronal excitability. Calcium dysregulation occurs within 10-20 minutes of exposure to tat-CN21; a time-course that correlates with maximal fluorescent uptake of tat-based peptides in our cortical cultures (12) . Although L-type voltage-gated calcium channels do not appear to contribute to calcium dysregulation following CaMKII inhibition, ion channels regulating neuronal activity (voltagegated sodium channels and N-type voltage-gated calcium channel) are critical for this process. Consistent with synaptic coupling required for calcium dysregulation, we observed that functional glutamate receptors (AMPA-and NMDA-subtypes) as well as elevated glutamate to be necessary for this process. While synaptic NMDA-Rs appeared to largely dictate calcium dysregulation and neuronal toxicity to CaMKII inhibition, we cannot rule out a contribution played by extrasynaptic NMDA-Rs in these processes. The involvement of both synaptic and extrasynaptic NMDA-Rs in calcium dysregulation and toxicity is reasonable considering that elevated levels of glutamate appear to accumulate in the media over time, with enhanced extracellular glutamate levels observed as early as 20 minutes following exposure to CaMKII inhibitors. Thus, while increased synaptic transmission may be necessary, it is possible that once glutamate accumulates in the milieu, it can also activate receptors outside of the synaptic cleft. Interestingly, exposure to elevated glutamate using conditioned media or exogenous glutamate is not toxic in the absence of CaMKII inhibition, suggesting that glutamate by itself is not sufficient for neurotoxicity in the absence of CaMKII inhibition. However, the elevated extracellular glutamate in conjunction with CaMKII inhibition appears to be essential to both calcium dysregulation and neurotoxicity, as enzymatic buffering of extracellular glutamate or pharmacological inhibition of the AMPA or NMDA receptors prevents calcium dysregulation. The fact that media exchange after 4 hours prevents neuronal toxicity to CaMKII inhibition is consistent with these observations, further supporting an important functional and temporal association between CaMKII inhibition and neuronal activity in this form of neurotoxicity.
Although our data does not rule out the possibility that elevated extracellular glutamate is produced by cell lysis, the observation that an increase in the number of action potentials induced by a depolarizing current following CaMKII inhibition by localized delivery of the CN21 inhibitor to individual cortical neurons supports the hypothesis that CaMKII inhibition directly enhances neuronal excitability. This acute response in neuronal excitability to CaMKII inhibition is novel. However, genetic knock down of αCaMKII in mice (34) or neuronal cultures by siRNA (43) support these findings. Thus, results from experiments examining the effect of CaMKII inhibition via pharmacological (this study) or genetic approaches (34, 43) support the hypothesis that CaMKII is a major regulator of neuronal excitability.
Our experiments favor a model whereby the sustained inhibition of CaMKII activity instigated a vicious cycle of sustained increases in intracellular calcium due to sustained glutamate release. In essence, CaMKII inhibition initiates an excitotoxic cycle by increasing neuronal excitability which subsequently supports enhanced glutamate levels in the media; a feed forward cycle that can be broken by preventing neuronal activity, blocking calcium dysregulation or by removing extracellular glutamate. These data suggest that CaMKII may be viewed to function in neurons as a brake for glutamate-excitation and/or as a master regulator of neuronal excitability and calcium homeostasis. Finally, the observed results do not appear to be limited to highly purified cortical cultures, as co-cultures of cortical neurons with astrocytes also display neuronal death following CaMKII inhibition. We cannot rule out the potential of glial function or viability being altered following CaMKII inhibition in mixed cultures, as glial cells also express CaMKII (CaMKII (44)), thus on-going experiments will need to examine consequences of CaMKII inhibition in astrocyte function and survival.
How could CaMKII inhibition impact calcium-induced neuronal death during ischemia and other excitotoxic stimuli? CaMKII has been shown to inactivate in the core of an ischemic insult in vivo as well as in the surrounding penumbral tissue (8); a phenomena also observed following aberrant neuronal activity in epilepsy (45) . The mechanism of CaMKII inactivation in these diseases is not well understood, but it is known that CaMKII proteolysis is preceeded by post-translational modifications (46) , including a soluble to particulate transition consistent with CaMKII aggregation following ischemia (7, 8, 47) . Inactivation associated with aggregation is consistent with CaMKII self-association; a form of catalytic aggregation that requires calciumCaM activation and is maximized under ischemic conditions (i.e. reduced energy) (48, 49) . In the current study, we have attempted to mimic one consequence of CaMKII selfassociation via pharmacological inhibition of enzymatic activity. Similar to in vivo studies characterizing functional changes in CaMKII associated with aberrant neuronal activity, we have observed a sustained loss of activatable CaMKII with long-term tat-CN21 exposure in cultured cortical neurons.
This sustained inactivation and transition of CaMKII from the soluble to particulate fractions has been previously shown to also accompany excitotoxic glutamate-glycine insults in neuronal cultures (12, 49) . An intriguing hypothesis is that the neuroprotection produced by acute exposure to CaMKII inhibitors may be limiting neurotoxicity to excitotoxic glutamate/glycine challenges by paradoxically preventing excitotoxic-induced CaMKII inactivation-aggregation.
Independent of this speculation, the present results indicate that sustained inactivation of CaMKII leads to neuronal cell death through engagement of apoptotic/necrotic pathways induced by calcium dysregulation and hyperexcitability, which contributes to the decreased capacity of neurons to cope with excitatory insults. These data may provide further mechanistic insight into the increased infarct size observed within αCaMKII knock-out animals (18) , and moreover, to the phenomenon of expanding neuronal damage in the ischemic penumbra. Peri-infarct depolarizations have been shown to underlie the progression of neuronal damage from the core throughout the penumbra (50) (51) (52) ] C , (mean ± SEM) before and after application of 10 µM tat-CN21, tat-CN21Ala, or tat. E, Neuronal intracellular calcium levels (mean ± SEM) before (-300 to 0 seconds) and after (0 to 1200 seconds) application of 10 µM tat-CN21, tat-CN21Ala, or tat, as measured by Fluo-4 (n=4).
F, Average integral of fluorescent intensity from 0-1200 seconds in E (mean ± SEM, n=3-6) with application of CaMKII inhibitors with and without pharmacological blockers of neuronal excitability. The integral was normalized to the calcium influx observed with application of 10 µM tat-CN21. *p<0.05 compared to tat-CN21 alone (One-Way ANOVA, post-hoc Dunnett's test). , n=4-8) in neuronal media following incubation with 10 µM tat-CN21 for 24 hours with and without co-application of glutamate pyruvate transaminase (GPT)/pyruvate, GPT alone, or boiled GPT/pyruvate. *p<0.05 compared to control while #p<0.05 compared to tat-CN21/GPT/pyruvate treatment (One-Way ANOVA, post-hoc Dunnett's test). B, Neuronal intracellular calcium levels (mean ± SEM, n=3) following application of tat-CN21 in the presence or absence of GPT/pyruvate. Bar graph inset indicates the average integral from 0-1200 seconds (mean ± SEM, n=3) for these treatment groups. C, Neuronal death (mean ± SEM, n=3-6) after 24 hour treatment with 10 µM tat-CN21 alone or coapplication with GPT/pyruvate, GPT alone, or boiled GPT/pyruvate. *p<0.05 compared to control while #p<0.05 compared to tat-CN21/GPT/pyruvate treatment (One-Way ANOVA, posthoc Dunnett's test). A, Average integral of fluorescent intensity from 0-1200 seconds (mean ± SEM, n=3-6) reflecting calcium influx in control neurons, or neurons subjected to treatment with tat-CN21 alone or in combination with 20 µM MK-801 or in combination with a prior synaptic NMDA-R blockade. To block synaptic NMDA-Rs before tat-CN21 treatment, 10 µM bicuculline was applied to allow synaptic activity, followed by the addition of 20 µM MK-801 to inhibit the synaptic NMDA-Rs opened as a result of this synaptic activity. *p<0.05 compared to control while #p<0.05 compared to tat-CN21 (One-Way ANOVA, post-hoc Dunnett's test). B, Neuronal death (mean ± SEM, n=4-24) after 24 hour treatment with 10 µM tat-CN21 alone or in the presence of 20 µM MK-801, 10 µM ifenprodil, 1 µM memantine, or 200 nM TTX. *p<0.05 compared to control while #p<0.05 compared to tat-CN21 (One-Way ANOVA, post-hoc Dunnett's test). 
